TCDAQ — Tricida Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $115.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -161.51% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.
Directors
- Klaus Veitinger NEC (59)
- Gerrit Klaerner PRE (50)
- Geoffrey Parker CFO (56)
- Robert Mckague EVP (57)
- Dawn Parsell EVP (58)
- Robert Alpern IND (70)
- David Bonita IND (45)
- Sandra Coufal IND (57)
- Kathryn Falberg IND (60)
- David Hirsch IND (50)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- May 22nd, 2013
- Public Since
- June 28th, 2018
- No. of Shareholders
- 216
- No. of Employees
- 57
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 58,028,254
- Address
- 7000 Shoreline Court, Suite 201, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.tricida.com/
- Phone
- +1 4154297800
- Auditors
- Ernst & Young LLP
Upcoming Events for TCDAQ
Q3 2023 Tricida Inc Earnings Release
Similar to TCDAQ
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Ayala Pharmaceuticals
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Tricida share price?
As of Today at 01:22 UTC, shares in Tricida are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Tricida share price performed this year?
Shares in Tricida last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Tricida share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for Tricida?
The overall consensus recommendation for Tricida is Sell. You can view the full broker recommendation list by unlocking its StockReport.
What is the Tricida dividend yield?
Tricida does not currently pay a dividend.
Does Tricida pay a dividend?
Tricida does not currently pay a dividend.
When does Tricida next pay dividends?
Tricida does not currently pay a dividend.
How do I buy Tricida shares?
To buy shares in Tricida you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tricida?
As of the previous close price of $0.00, shares in Tricida had a market capitalisation of $0.00m.
Where are Tricida shares listed?
Here are the trading details for Tricida:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TCDAQ
What kind of share is Tricida?
Based on an overall assessment of its quality, value and momentum Tricida is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tricida share price forecast for 2023?
The analyst consensus target price for shares in Tricida is $20.00. That is 199999900% above the last closing price of $0.00.
Analysts covering Tricida currently have a consensus Earnings Per Share (EPS) forecast of -$1.88 for the next financial year.
What is the trend in the Tricida share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tricida. Over the past six months, its share price has underperformed the S&P500 Index by -99.99%.
As of the last closing price of $0.00, shares in Tricida were trading -100% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tricida PE Ratio?
The Tricida PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tricida?
Tricida's management team is headed by:
- Klaus Veitinger - NEC
- Gerrit Klaerner - PRE
- Geoffrey Parker - CFO
- Robert Mckague - EVP
- Dawn Parsell - EVP
- Robert Alpern - IND
- David Bonita - IND
- Sandra Coufal - IND
- Kathryn Falberg - IND
- David Hirsch - IND